June 2015, Vol 8, No 4
Treatment Sequences and Pharmacy Costs of 2 New Therapies for Metastatic Castration-Resistant Prostate Cancer
Lorie A. Ellis, PhD, Laurence Gozalo, PhD, Marie-Hélène Lafeuille, MA, Patrick Lefebvre, MA, Scott McKenzie, MD, Dominic Pilon, MA
Estimating the Costs of Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma: A Model Framework
Anuja Roy, PhD, MBA, Jonathan K. Kish, PhD, MPH, Lisa Bloudek, PharmD, MS, David S. Siegel, MD, PhD, Sundar Jagannath, MD, Denise Globe, PhD, Emil T. Kuriakose, MD, Kristen Migliaccio-Walle, BS
Multiple myeloma is a malignant B-cell neoplasm of terminally differentiated plasma cells that accumulate in the bone marrow and frequently invade the adjacent bone, leading to bone destruction and marrow failure.
The Rationale for Comparing the Costs of Competing Treatment Options in Oncology
Oncology Innovation and Challenging Choices: Balancing Value and Funding Priorities in Light of an Abundance of New Treatment Options
Cancer is already the largest clinical area of drug spending in the United States, and a cluster of innovative medicines utilizing new mechanisms of action for patients with a wide variety of tumor types promise to further increase cancer-related spending.
Results 1 - 6 of 6